This 6-month open label study will evaluate the long term safety of bosentan (via oxygen
saturation) and efficacy (exercise capacity) in patients who have completed the BREATHE-5
study (PAH related to Eisenmenger physiology). Treatment duration is 6 months.
Minimum age: 12 Years.
Maximum age: N/A.
Gender(s): Both.
Royal Prince Alfred Hospital - Central Clinical School, Camperdown NSW 2050, Australia
The Royal Melbourne Hospital, Victoria 3050, Australia
Universitatsklinikum fur Innere Medizin II, Wien AT-1090, Austria
UZ Gasthuisberg, Leuven BE-3000, Belgium
Hospital Necker-Enfants Malades, Paris 75007, France
Herzzentrum NRW, Bad Oeynhausen D-32545, Germany
Deutsches Herzzentrum Munchen, Munchen D-80636, Germany
University of Bologna, Bologna 40138, Italy
San Matteo Hospital, Pavia 27100, Italy
Academisch Ziekenhuis Groningen, Groningen 9713 GZ, Netherlands
Unidad Medico Quirurgica de Cardiologia - Edificio General, Madrid 28046, Spain
Scottish Vascular Unit - Western Infirmary, Glasgow G11 6NT, United Kingdom
Royal Brompton Hospital, London SW3 6NP, United Kingdom
The Peter Lougheed Centre, Calgary, Alberta T1Y 6J4, Canada
BACH Pulmonary Hypertension Service, Boston, Massachusetts 02115, United States
Toronto General Hospital, Toronto, Ontario M5G 2C4, Canada
Texas Children's Hospital, Houston, Texas 77030-2303, United States